Covaxin shields from B.1.617’

Covaxin shields from B.1.617’

People vaccinated with it protected against double mutant variant: study

29/04/2021

Safe bet: A health worker giving a shot of Covaxin in New Delhi. SHIV KUMAR PUSHPAKAR Shiv Kumar Pushpakar

R. PrasadCHENNAI

A study has found that people who have been vaccinated with Covaxin have protection against the double mutant (B.1.617) variant first found in India. A preprint of the study carried out by the Indian Council of Medical Research (ICMR) and Bharat Biotech researchers has been posted in biorXiv. Preprints are yet to be peer-reviewed and published in medical journals.

So far, 21 countries have detected the B.1.617 variant. Of those, the majority of cases has been reported from India.

The researchers used the sera collected from 28 people who had participated in the Covaxin phase-2 trial. They also collected sera samples from 17 people who were infected with older strains of SARS-CoV-2 virus and had recovered. “The study found that the neutralising capacity against the double mutant [B.1.617] variant was found to be good in both groups — people who have received the vaccine and those who have recovered from COVID-19,” say Dr. Samiran Panda, a senior scientist at ICMR and one of the co-authors of the preprint. “Compared with people who have recovered from COVID-19, the ability of the sera of vaccinated people to neutralise the B.1.617 variant was found to be two-fold less.”

An earlier study had found that Covaxin neutralises the B.1.1.7 variant first found in the U.K.

“The assurance of neutralisation of B.1.617 variant with sera of Covaxin vaccines and recovered COVID-19 sera will provide the much-needed boost for the COVID-19 vaccination programme in India,” the authors write.

Speaking to presspersons during a conference call on April 27, Dr. Antony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), said: “Despite the real difficulty that we’re seeing in India, vaccination could be a very important antidote against this [variant].”

The B.1.617 variant has two mutations — E484Q and L425R — of concern. These mutations are found in the receptor-binding domain of the spike protein. Though how the two mutations behave individually is well-known, the combined effect of these mutations when present together is not known. “Further studies are needed to understand the transmissibility and infectivity of the B.1.617 variant,” the authors write.